This article is more than 5 years old. Information may no longer be current.
FDA: US metformin products safe from NDMA contamination
FDA-approved metformin products do not contain dangerous levels of nitrosodimethylamine, or NDMA, according to laboratory results released by the FDA.
As Healio previously reported, NDMA, which is a potentially carcinogenic agent, was found in metformin products in non-U.S. countries, causing the FDA to investigate metformin in the United States. Based on this investigation, the FDA found “not detectable to low levels” of NDMA in FDA-approved metformin, according to a press release.
In the release, the FDA advised the continued use of metformin for its indicated use for people with diabetes and stated that it will not be recalling U.S.-based metformin.
Enough NDMA evidence has previously been found in other medications to warrant recalls, including for the angiotensin receptor blocker valsartan as well as generic forms of Zantac (ranitidine). – by Phil Neuffer